{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:17:38Z","timestamp":1793506658937,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1176780"],"award-info":[{"award-number":["OPP1176780"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["089276\/B\/09\/7"],"award-info":[{"award-number":["089276\/B\/09\/7"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Schistosomiasis is a neglected tropical disease, targeted by the World Health Organization for reduction in morbidity by 2020. It is caused by parasitic flukes that spread through contamination of local water sources. Traditional control focuses on mass drug administration, which kills the majority of adult worms, targeted at school-aged children. However, these drugs do not confer long-term protection and there are concerns over the emergence of drug resistance. The development of a vaccine against schistosomiasis opens the potential for control methods that could generate long-lasting population-level immunity if they are cost-effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using an individual-based transmission model, matched to epidemiological data, we compared the cost-effectiveness of a range of vaccination programmes against mass drug administration, across three transmission settings. Health benefit was measured by calculating the heavy-intensity infection years averted by each intervention, while vaccine costs were assessed against robust estimates for the costs of mass drug administration obtained from data. We also calculated a critical vaccination cost, a cost beyond which vaccination might not be economically favorable, by benchmarking the cost-effectiveness of potential vaccines against the cost-effectiveness of mass drug administration, and examined the effect of different vaccine protection durations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that sufficiently low-priced vaccines can be more cost-effective than traditional drugs in high prevalence settings, and can lead to a greater reduction in morbidity over shorter time-scales. MDA or vaccination programmes that target the whole community generate the most health benefits, but are generally less cost-effective than those targeting children, due to lower prevalence of schistosomiasis in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ultimate cost-effectiveness of vaccination will be highly dependent on multiple vaccine characteristics, such as the efficacy, cost, safety and duration of protection, as well as the subset of population targeted for vaccination. However, our results indicate that if a vaccine could be developed with reasonable characteristics and for a sufficiently low cost, then vaccination programmes can be a highly cost-effective method of controlling schistosomiasis in high-transmission areas. The population-level immunity generated by vaccination will also inevitably improve the chances of interrupting transmission of the disease, which is the long-term epidemiological goal.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-019-3749-4","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T16:57:22Z","timestamp":1571849842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Vaccination or mass drug administration against schistosomiasis: a hypothetical cost-effectiveness modelling comparison"],"prefix":"10.1186","volume":"12","author":[{"given":"Benjamin S.","family":"Collyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo C.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. D\u00e9irdre","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt J.","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"3749_CR1","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","volume":"383","author":"DG Colley","year":"2014","unstructured":"Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383:2253\u201364.","journal-title":"Lancet."},{"key":"3749_CR2","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1017\/S0031182009000493","volume":"136","author":"MJ Doenhoff","year":"2009","unstructured":"Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology. 2009;136:1825\u201335.","journal-title":"Parasitology."},{"key":"3749_CR3","volume-title":"Helminth control in school-age children: a guide for managers of control programmes","author":"WHO","year":"2011","unstructured":"WHO. Helminth control in school-age children: a guide for managers of control programmes. Geneva: World Health Organization; 2011."},{"key":"3749_CR4","unstructured":"Uniting to Combat NTDs: Ending Neglected Tropical Diseases: A gateway to Universal Health Coverage, Fifth progress report on the London Declaration on NTDs; 2017."},{"key":"3749_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.actatropica.2009.11.011","volume":"113","author":"D Croce","year":"2010","unstructured":"Croce D, Porazzi E, Foglia E, Restelli U, Sinuon M, Socheat D, et al. Cost-effectiveness of a successful schistosomiasis control programme in Cambodia (1995\u20132006). Acta Trop. 2010;113:279\u201384.","journal-title":"Acta Trop."},{"key":"3749_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/tropicalmed4010030","volume":"4","author":"V Khieu","year":"2019","unstructured":"Khieu V, Sayasone S, Muth S, Kirinoki M, Laymanivong S, Ohmae H, et al. Elimination of schistosomiasis mekongi from endemic areas in Cambodia and the Lao People\u02bcs Democratic Republic: current status and plans. Trop Med Infect Dis. 2019;4:30.","journal-title":"Trop Med Infect Dis."},{"key":"3749_CR7","doi-asserted-by":"publisher","first-page":"e0006061","DOI":"10.1371\/journal.pntd.0006061","volume":"11","author":"AE Phillips","year":"2017","unstructured":"Phillips AE, Gazzinelli-Guimaraes PH, Aurelio HO, Ferro J, Nala R, Clements M, et al. Assessing the benefits of five years of different approaches to treatment of urogenital schistosomiasis: A SCORE project in northern Mozambique. PLoS Negl Trop Dis. 2017;11:e0006061.","journal-title":"PLoS Negl Trop Dis."},{"key":"3749_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/infdis\/jix496","volume":"216","author":"RE Wiegand","year":"2017","unstructured":"Wiegand RE, Mwinzi PNM, Montgomery SP, Chan YL, Andiego K, Omedo M, et al. A persistent hotspot of Schistosoma mansoni infection in a five-year randomized trial of praziquantel preventative chemotherapy strategies. J Infect Dis. 2017;216:1425\u201333.","journal-title":"J Infect Dis."},{"key":"3749_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13071-015-0983-2","volume":"8","author":"H Elmorshedy","year":"2015","unstructured":"Elmorshedy H, Bergquist R, Emam Abou N, Eassa S, Elsakka E, Barakat R. Can human schistosomiasis mansoni control be sustained in high-risk transmission foci in Egypt? Parasit Vectors. 2015;8:372.","journal-title":"Parasit Vectors."},{"key":"3749_CR10","doi-asserted-by":"publisher","first-page":"e0006717","DOI":"10.1371\/journal.pntd.0006717","volume":"12","author":"J Toor","year":"2018","unstructured":"Toor J, Turner HC, Truscott JE, Werkman M, Phillips AE, Alsallaq R, et al. The design of schistosomiasis monitoring and evaluation programmes: the importance of collecting adult data to inform treatment strategies for Schistosoma mansoni. PLoS Negl Trop Dis. 2018;12:e0006717.","journal-title":"PLoS Negl Trop Dis."},{"key":"3749_CR11","doi-asserted-by":"publisher","first-page":"S245","DOI":"10.1093\/cid\/ciy001","volume":"66","author":"J Toor","year":"2018","unstructured":"Toor J, Alsallaq R, Truscott JE, Turner HC, Werkman M, Gurarie D, et al. Are we on our way to achieving the 2020 goals for schistosomiasis morbidity control using current World Health Organization guidelines? Clin Infect Dis. 2018;66:S245\u201352.","journal-title":"Clin Infect Dis."},{"key":"3749_CR12","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1016\/j.vaccine.2009.02.096","volume":"27","author":"G Ahmad","year":"2009","unstructured":"Ahmad G, Zhang W, Torben W, Damian RT, Wolf RF, White GL, et al. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine. 2009;27:2830\u20137.","journal-title":"Vaccine."},{"key":"3749_CR13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1093\/infdis\/jiu031","volume":"209","author":"S Karmakar","year":"2014","unstructured":"Karmakar S, Zhang W, Ahmad G, Torben W, Alam MU, Le L, et al. Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons. J Infect Dis. 2014;209:1929\u201340.","journal-title":"J Infect Dis."},{"key":"3749_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/nyas.13866","volume":"1425","author":"AJ Siddiqui","year":"2018","unstructured":"Siddiqui AJ, Molehin AJ, Zhang W, Ganapathy PK, Kim E, Rojo JU, et al. Sm-p80-based vaccine trial in baboons: efficacy when mimicking natural conditions of chronic disease, praziquantel therapy, immunization, and Schistosoma mansoni re-encounter. Ann N Y Acad Sci. 2018;1425:19\u201337.","journal-title":"Ann N Y Acad Sci."},{"key":"3749_CR15","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00436-014-3879-8","volume":"113","author":"W Zhang","year":"2014","unstructured":"Zhang W, Ahmad G, Le L, Rojo JU, Karmakar S, Tillery KA, et al. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon. Parasitol Res. 2014;113:2239\u201350.","journal-title":"Parasitol Res."},{"key":"3749_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/nyas.13942","volume":"1425","author":"W Zhang","year":"2018","unstructured":"Zhang W, Molehin AJ, Rojo JU, Sudduth J, Ganapathy PK, Kim E, et al. Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy. Ann N Y Acad Sci. 2018;1425:38\u201351.","journal-title":"Ann N Y Acad Sci."},{"key":"3749_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/infdis\/jir545","volume":"204","author":"G Ahmad","year":"2011","unstructured":"Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF, et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis. 2011;204:1437\u201349.","journal-title":"J Infect Dis."},{"key":"3749_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1086\/651147","volume":"201","author":"W Zhang","year":"2010","unstructured":"Zhang W, Ahmad G, Torben W, Noor Z, Le L, Damian RT. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis. 2010;201:1105\u201312.","journal-title":"J Infect Dis."},{"key":"3749_CR19","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0264-410X(97)00071-6","volume":"15","author":"MS Chan","year":"1997","unstructured":"Chan MS, Woolhouse MEJ, Bundy DAP. Human schistosomiasis: potential long term consequences of vaccination programmes. Vaccine. 1997;15:1545\u201350.","journal-title":"Vaccine."},{"key":"3749_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0001-706X(95)91938-5","volume":"59","author":"HL Guyatt","year":"1995","unstructured":"Guyatt HL, Evans D. Desirable characteristics of a schistosomiasis vaccine: some implications of a cost-effectiveness analysis. Acta Trop. 1995;59:197\u2013209.","journal-title":"Acta Trop."},{"key":"3749_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1017\/S0031182000052288","volume":"90","author":"RM Anderson","year":"1985","unstructured":"Anderson RM, Medley GF. Community control of helminth infections of man by mass and selective chemotherapy. Parasitology. 1985;90:629\u201360.","journal-title":"Parasitology."},{"key":"3749_CR22","doi-asserted-by":"publisher","first-page":"e0005544","DOI":"10.1371\/journal.pntd.0005544","volume":"11","author":"RA Alsallaq","year":"2017","unstructured":"Alsallaq RA, Gurarie D, Ndeffo Mbah M, Galvani A, King C. Quantitative assessment of the impact of partially protective anti-schistosomiasis vaccines. PLoS Negl Trop Dis. 2017;11:e0005544.","journal-title":"PLoS Negl Trop Dis."},{"key":"3749_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13071-017-2227-0","volume":"10","author":"A Stylianou","year":"2017","unstructured":"Stylianou A, Hadjichrysanthou C, Truscott JE, Anderson RM. Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities. Parasit Vectors. 2017;10:294.","journal-title":"Parasit Vectors."},{"key":"3749_CR24","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198545996.001.0001","volume-title":"Infectious diseases of humans: dynamics and control","author":"RM Anderson","year":"1991","unstructured":"Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press; 1991."},{"key":"3749_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13071-016-1681-4","volume":"9","author":"D Gurarie","year":"2016","unstructured":"Gurarie D, King CH, Yoon N, Li E. Refined stratified-worm-burden models that incorporate specific biological features of human and snail hosts provide better estimates of Schistosoma diagnosis, transmission, and control. Parasit Vectors. 2016;9:428.","journal-title":"Parasit Vectors."},{"key":"3749_CR26","doi-asserted-by":"publisher","first-page":"E584","DOI":"10.1073\/pnas.1708729114","volume":"115","author":"NC Lo","year":"2018","unstructured":"Lo NC, Gurarie D, Yoon N, Coulibaly JT, Bendavid E, Andrews JR, et al. Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis. Proc Natl Acad Sci USA. 2018;115:E584\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3749_CR27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.trstmh.2008.02.016","volume":"102","author":"S Sow","year":"2008","unstructured":"Sow S, Polman K, Vereecken K, Vercruysse J, Gryseels B, de Vlas SJ. The role of hygienic bathing after defecation in the transmission of Schistosoma mansoni. Trans R Soc Trop Med Hyg. 2008;102:542\u20137.","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"3749_CR28","first-page":"397","volume":"14","author":"N Katz","year":"1972","unstructured":"Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1972;14:397\u2013400.","journal-title":"Rev Inst Med Trop Sao Paulo."},{"key":"3749_CR29","volume-title":"Bench aids for the diagnosis of intestinal parasites","author":"WHO","year":"1994","unstructured":"WHO. Bench aids for the diagnosis of intestinal parasites. Geneva: World Health Organization; 1994."},{"key":"3749_CR30","volume-title":"Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee","author":"WHO","year":"2002","unstructured":"WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. Geneva: World Health Organization; 2002."},{"key":"3749_CR31","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1017\/S0031182003004128","volume":"127","author":"M Booth","year":"2003","unstructured":"Booth M, Vounatsou P, Ngoran EK, Tanner M, Utzinger J. The influence of sampling effort and the performance of the Kato\u2013Katz technique in diagnosing Schistosoma mansoni and hookworm co-infections in rural C\u00f4te d\u02bcIvoire. Parasitology. 2003;127:525\u201331.","journal-title":"Parasitology."},{"key":"3749_CR32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/0035-9203(81)90148-6","volume":"75","author":"A Hall","year":"1981","unstructured":"Hall A. Quantitative variability of nematode egg counts in faeces: a study among rural Kenyans. Trans R Soc Trop Med Hyg. 1981;75:682\u20137.","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"3749_CR33","doi-asserted-by":"publisher","first-page":"e0006043","DOI":"10.1371\/journal.pntd.0006043","volume":"11","author":"M Burnim","year":"2017","unstructured":"Burnim M, Ivy JA, King CH. Systematic review of community-based, school-based, and combined delivery modes for reaching school-aged children in mass drug administration programs for schistosomiasis. PLoS Negl Trop Dis. 2017;11:e0006043.","journal-title":"PLoS Negl Trop Dis."},{"key":"3749_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s13071-015-1157-y","volume":"8","author":"RM Anderson","year":"2015","unstructured":"Anderson RM, Turner HC, Farrell SH, Yang J, Truscott JE. What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? Parasit Vectors. 2015;8:553.","journal-title":"Parasit Vectors."},{"key":"3749_CR35","doi-asserted-by":"publisher","first-page":"e3286","DOI":"10.1371\/journal.pntd.0003286","volume":"8","author":"J Zwang","year":"2014","unstructured":"Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis. 2014;8:e3286.","journal-title":"PLoS Negl Trop Dis."},{"key":"3749_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.epidem.2017.02.002","volume":"18","author":"L Dyson","year":"2017","unstructured":"Dyson L, Stolk WA, Farrell SH, Hollingsworth TD. Measuring and modelling the effects of systematic non-adherence to mass drug administration. Epidemics. 2017;18:56\u201366.","journal-title":"Epidemics."},{"key":"3749_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13071-017-2141-5","volume":"10","author":"HC Turner","year":"2017","unstructured":"Turner HC, Truscott JE, Bettis AA, Farrell SH, Deol AK, Whitton JM, et al. Evaluating the variation in the projected benefit of community-wide mass treatment for schistosomiasis: implications for future economic evaluations. Parasit Vectors. 2017;10:213.","journal-title":"Parasit Vectors."},{"key":"3749_CR38","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis","author":"RM Baltussen","year":"2003","unstructured":"Baltussen RM, Adam T, Tan-Torres Edejer T, Hutubessy RC, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003."},{"key":"3749_CR39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/351757a0","volume":"351","author":"ME Woolhouse","year":"1991","unstructured":"Woolhouse ME, Taylor P, Matanhire D, Chandiwana SK. Acquired immunity and epidemiology of Schistosoma haematobium. Nature. 1991;351:757\u20139.","journal-title":"Nature."},{"key":"3749_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0169-4758(97)01207-6","volume":"14","author":"NR Bergquist","year":"1998","unstructured":"Bergquist NR, Colley DG. Schistosomiasis vaccine:research to development. Parasitol Today. 1998;14:99\u2013104.","journal-title":"Parasitol Today."},{"key":"3749_CR41","volume-title":"World Health Organization Global market study: HPV vaccines","author":"WHO","year":"2019","unstructured":"WHO. World Health Organization Global market study: HPV vaccines. Geneva: World Health Organization; 2019."},{"key":"3749_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/archdischild-2012-302338","volume":"98","author":"MA Barry","year":"2013","unstructured":"Barry MA, Simon GG, Mistry N, Hotez PJ. Global trends in neglected tropical disease control and elimination: impact on child health. Arch Dis Child. 2013;98:635\u201341.","journal-title":"Arch Dis Child."},{"key":"3749_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/bs.apar.2016.06.003","volume":"94","author":"RM Anderson","year":"2016","unstructured":"Anderson RM, Turner HC, Farrell SH, Truscott JE. Studies of the transmission dynamics, mathematical model development and the control of schistosome parasites by mass drug administration in human communities. Adv Parasitol. 2016;94:199\u2013246.","journal-title":"Adv Parasitol."},{"key":"3749_CR44","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/0169-4758(92)90144-Q","volume":"8","author":"SJ De Vlas","year":"1992","unstructured":"De Vlas SJ, Gryseels B. Underestimation of Schistosoma mansoni prevalences. Parasitol Today. 1992;8:274\u20137.","journal-title":"Parasitol Today."},{"key":"3749_CR45","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1017\/S003118200006371X","volume":"104","author":"SJ De Vlas","year":"1992","unstructured":"De Vlas SJ, Gryseels B, Van Oortmarssen GJ, Polderman AM, Habbema JD. A model for variations in single and repeated egg counts in Schistosoma mansoni infections. Parasitology. 1992;104:451\u201360.","journal-title":"Parasitology."},{"key":"3749_CR46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S0950268800058453","volume":"115","author":"MS Chan","year":"1995","unstructured":"Chan MS, Guyatt HL, Bundy DA, Booth M, Fulford AJ, Medley GF. The development of an age structured model for schistosomiasis transmission dynamics and control and its validation for Schistosoma mansoni. Epidemiol Infect. 1995;115:325\u201344.","journal-title":"Epidemiol Infect."},{"key":"3749_CR47","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/297557a0","volume":"297","author":"RM Anderson","year":"1982","unstructured":"Anderson RM, May RM. Population dynamics of human helminth infections: control by chemotherapy. Nature. 1982;297:557\u201363.","journal-title":"Nature."},{"key":"3749_CR48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/S0031182000080896","volume":"110","author":"AJ Fulford","year":"1995","unstructured":"Fulford AJ, Butterworth AE, Ouma JH, Sturrock RF. A statistical approach to schistosome population dynamics and estimation of the life-span of Schistosoma mansoni in man. Parasitology. 1995;110:307\u201316.","journal-title":"Parasitology."},{"key":"3749_CR49","doi-asserted-by":"publisher","first-page":"20130435","DOI":"10.1098\/rstb.2013.0435","volume":"369","author":"R Anderson","year":"2014","unstructured":"Anderson R, Truscott J, Hollingsworth TD. The coverage and frequency of mass drug administration required to eliminate persistent transmission of soil-transmitted helminths. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130435.","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"3749_CR50","unstructured":"Fitzpatrick C, Fleming FM, Madin-Warburton M, Schneider T, Meheus F, Asiedu K, et al. Benchmarks for the cost per person of mass treatment against neglected tropical diseases. https:\/\/healthy.shinyapps.io\/benchmark\/ (2016). Accessed 30 Nov 2018."},{"key":"3749_CR51","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/cid\/ciy741","volume":"68","author":"HC Turner","year":"2019","unstructured":"Turner HC, Toor J, Bettis AA, Hopkins AD, Kyaw SS, Onwujekwe O, et al. Valuing the unpaid contribution of community health volunteers to mass drug administration programs. Clin Infect Dis. 2019;68:1588\u201395.","journal-title":"Clin Infect Dis."},{"key":"3749_CR52","doi-asserted-by":"publisher","first-page":"e0005037","DOI":"10.1371\/journal.pntd.0005037","volume":"10","author":"C Fitzpatrick","year":"2016","unstructured":"Fitzpatrick C, Fleming FM, Madin-Warburton M, Schneider T, Meheus F, Asiedu K, et al. Benchmarking the cost per person of mass treatment for selected neglected tropical diseases: an approach based on literature review and meta-regression with web-based software application. PLoS Negl Trop Dis. 2016;10:e0005037.","journal-title":"PLoS Negl Trop Dis."},{"key":"3749_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/inthealth\/ihs010","volume":"5","author":"J Leslie","year":"2013","unstructured":"Leslie J, Garba A, Boubacar K, Yaye Y, Sebongou H, Barkire A, et al. Neglected tropical diseases: comparison of the costs of integrated and vertical preventive chemotherapy treatment in Niger. Int Health. 2013;5:78\u201384.","journal-title":"Int Health."},{"key":"3749_CR54","doi-asserted-by":"publisher","first-page":"e1326","DOI":"10.1371\/journal.pntd.0001326","volume":"5","author":"J Leslie","year":"2011","unstructured":"Leslie J, Garba A, Oliva EB, Barkire A, Tinni AA, Djibo A, et al. Schistosomiasis and soil-transmitted helminth control in Niger: cost effectiveness of school based and community distributed mass drug administration [corrected]. PLoS Negl Trop Dis. 2011;5:e1326.","journal-title":"PLoS Negl Trop Dis."},{"key":"3749_CR55","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1017\/S003118200007414X","volume":"105","author":"AJ Fulford","year":"1992","unstructured":"Fulford AJ, Butterworth AE, Sturrock RF, Ouma JH. On the use of age-intensity data to detect immunity to parasitic infections, with special reference to Schistosoma-Mansoni in Kenya. Parasitology. 1992;105:219\u201327.","journal-title":"Parasitology."},{"key":"3749_CR56","unstructured":"WHO. WHO PCT Databank. https:\/\/www.who.int\/neglected_diseases\/preventive_chemotherapy\/sch\/en\/ (2018). Accessed Nov 2018."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3749-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13071-019-3749-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3749-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T11:06:00Z","timestamp":1721905560000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-019-3749-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3749"],"URL":"https:\/\/doi.org\/10.1186\/s13071-019-3749-4","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"499"}}